Renalyse

CreatSens Health S. L. , based in Spain, focuses on developing innovative healthcare solutions for chronic kidney disease management, enhancing patient outcomes through remote health monitoring and diagnostics. Founded in 2017 and headquartered in Reus, Spain, CreatSens Health S.

L. specializes in chronic kidney disease (CKD) solutions. The company was co-founded by Marta Recasens and Tomàs Guinovart. As of October 2023, CreatSens has completed 2 funding deals, raising a total of EUR 1.

00 mn, with its most recent funding round being led by Fundación Botín, which also included Genesis Biomed as an investor. Renalyse by CreatSens specializes in innovative healthcare solutions for chronic kidney disease (CKD) management through its core product offerings, enabling remote health monitoring and diagnostics. Their flagship technology assesses key kidney function indicators using just a drop of blood, streamlining the diagnostic process for healthcare professionals and patients alike. The company's services are designed for primary care centers, hospitals, and individual patients, enhancing healthcare experiences via a cloud-based platform.

Renalyse's products are marketed in developed countries across Europe, North America, and other regions where CKD is prevalent. In 2023, Renalyse reported a revenue of EUR 478,334. 20, with an EBITDA of EUR 44,651. 80.

Revenue is generated through direct-to-consumer channels and business-to-business partnerships, including subscription services and transactional revenues from individual diagnostic tests. Following the recent funding round on October 9, 2023, where Renalyse raised EUR 1. 00 mn led by Fundación Botín, the company plans to utilize these funds to scale and accelerate the certification of its CKD diagnostic and monitoring device. There are ongoing plans to expand into new markets, targeting additional regions where CKD is a significant health concern.